MedAnnex Ltd is an award-winning Scottish biotechnology company developing innovative approaches to treating autoimmune diseases and other medical conditions.
Having recently closed a Series B investment, and supported by both the Scottish Investment Bank and Innovate UK, MedAnnex is collaborating with world-leading clinical experts to explore the huge therapeutic and commercial potential of our immunomodulatory technology.
MedAnnex begins cell line development at FUJIFILM Diosynth.
£1 million from Scottish Investment Bank completes £11 million funding for MedAnnex.
“ MedAnnex is a fantastic example of an ambitious Scottish company that’s developing innovative new treatments for patients globally. ”
Jim Watson, Director of Innovation & Enterprise Services at Scottish Enterprise
MedAnnex Ltd is a privately-owned, preclinical-stage biotechnology company based in Edinburgh, Scotland.
Established in 2009 by serial life sciences entrepreneur Professor Chris Wood (founder of Nucana, Bioenvision and 30 Technology), we are committed to extending and improving lives.
We have developed novel antibodies to specifically modulate the innate and adaptive immune systems to treat autoimmune disorders and various other serious diseases.
MedAnnex is undergoing rapid expansion in preparation for clinical trials and is working with internationally renowned experts at leading UK universities. In particular, we are collaborating with teams at University College London, led by Professor David Isenberg and Professor Claudia Mauri, at the University of Glasgow, under the directorship of Professor Carl Goodyear, and at Anglia Ruskin University, under the supervision of Professor Chris Parris.
Our recent £11million Series B investment, combined with grant funding from both Innovate UK and SMART: SCOTLAND, will accelerate our journey towards the clinic.
Follow MedAnnex on LinkedIn to keep up to date with the latest developments.
MedAnnex won an innovation award at Corporate LiveWire’s Healthcare & Life Sciences Awards 2018, in recognition of the huge potential of our patent-protected technology to treat autoimmune diseases.
Our novel approach uses antibodies to target annexin-A1 – a key stimulus in the autoimmune process – in order to modify the immune system at an earlier stage than existing therapies, reducing inflammation and disease severity. This approach could revolutionise the treatment of several debilitating and life-limiting autoimmune diseases and has already shown significant activity in experimental models of rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus (‘lupus’). Furthermore, in non-clinical testing, annexin-A1 modulation has shown a beneficial effect on anxiety and depression, which are common side effects of existing autoimmune disease treatments. MedAnnex is collaborating with an NHS NIHR Lupus Centre of Excellence to ensure that we realise the full potential of our novel therapeutic approach.
Our antibody technology is protected by a robust intellectual property portfolio which includes patents granted in all major territories. Feedback from leading clinicians and global pharma companies has confirmed that annexin-A1 is a unique target with major therapeutic potential.
In parallel with our autoimmune programme, MedAnnex has also generated promising early data concerning T cell modulation within other major disease areas.
Follow MedAnnex on LinkedIn to keep up to date with the latest developments.
MedAnnex is proud to collaborate with leading academic researchers, play an active role within several industry associations and provide extensive skills development opportunities.
Prof Chris Wood
(Founder/CMO/Executive Chairman)
A serial entrepreneur who has founded, managed and successfully exited a clutch of biotechnology companies, including Bioenvision Inc (NASDAQ: BIV), and NuCana plc (NASDAQ: NCNA).
Ian Abercrombie
(Chief Executive Officer)
25 years’ experience in both clinical development and commercial settings, including senior positions in Johnson & Johnson, Bioenvision, Genzyme, Caris Life Sciences and NuCana.
Dr Fiona Dempsey
(Director of Scientific Operations)
20 years' experience in biopharmaceutical cell biology, bioanalysis and bioprocesses. She has coordinated multiple UK and global drug development studies in compliance with GLP and GCP regulations.
Dr Henry Hays
(Scientific Project Manager)
Significant expertise in antibody development, having previously held a Senior Protein Scientist role with responsibility for the development, characterisation and scale-up of antibody drug conjugate (ADC) processes.
Prof Carl Goodyear
(Scientific Advisor)
Professor of Translational Immunology at the University of Glasgow's Institute of Infection, Immunity and Inflammation and Director of the GLAZgo Discovery Centre, exploring new treatment pathways for immunological diseases.
MedAnnex is a proud signatory of the Scottish Business Pledge, showing our commitment to building sustainable growth whilst maintaining fairness, equality, opportunity and innovation. We were delighted to be shortlisted as a finalist at Scotland's Life Sciences Annual Awards 2019, for ‘Outstanding Skills Development’.
As a small biotech company, MedAnnex has to remain streamlined and dynamic, with a clear focus on new ideas. Tapping in to the huge pool of young talent in our home city of Edinburgh and beyond is one way in which we achieve this.
We were proud to be chosen by Edinburgh Napier University as a case study in successful work placement practice, featuring in a video presentation at the university’s employers’ event.
MedAnnex has also forged close ties with the University of Edinburgh and is involved in developing the Life Science stars of the future, not only by attending the university’s careers events and AIM (Academia Industry Meeting) days but also by hosting MSc students in project-based work placements.
MedAnnex is involved in promoting careers in industry to students at the University of Glasgow too and currently sponsors a four-year PhD at the university.
MedAnnex strongly believes in the importance of investing in our workforce to ensure that we continue to be an effective team with diverse but complementary skills and experience. By fostering a culture of learning, enhancing the expertise of our team and offering skills development opportunities wherever possible, we safeguard the future of MedAnnex in the fast-paced, innovation-driven world of biotechnology, and play our part in enhancing the pool of talent in Scotland to help accelerate the growth of our Life Sciences sector towards the £8bn target for 2025.
MedAnnex begins cell line development at FUJIFILM Diosynth.
£1 million from Scottish Investment Bank completes £11 million funding for MedAnnex.
Ian Abercrombie joins MedAnnex as Chief Executive Officer.
MedAnnex announces £11.5 million equity investment, led by Morningside Ventures.
MedAnnex welcomes a fresh intake of summer work placement students from UK Universities.
MedAnnex attends the Milner Therapeutics Symposium in Cambridge.
Email: [email protected]
1 Summerhall Place,
Techcube 3.5,
Edinburgh
EH9 1PL
Telephone: +44 (0) 131 290 2133
63 Grosvenor Street,
London
W1K 3JG
Telephone: +44 (0) 207 493 4546
